MRNA · Company research
Moderna, Inc. (MRNA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
47records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? | BioNTech faces mounting clinical setbacks in its cancer vaccine pipeline, including a halted Phase 2 trial for autogene cevumeran and BNT113's failure to meet a primary endpoint in head and neck cancer trials. With COVID-19 vaccine revenues declining sharply (down 60% YoY) and the company unprofitable, investors must weigh the deep pipeline potential against significant uncertainty. The stock is recommended only for risk-tolerant investors. | View source ↗ | The Motley Fool | Oct 18, 2026 | neutral | 0 | 1 |
| Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline - The Motley Fool | Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline The Motley Fool | View source ↗ | The Motley Fool | Oct 17, 2026 | neutral | 0 | 0.6 |
| Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline | BioNTech has 16.6 billion euros in cash and is advancing 14 pivotal oncology trials, positioning itself to transition from a COVID-19 vaccine maker to a major cancer treatment company. With a diversified pipeline including promising candidates like pumitamig and a $1 billion share repurchase program, the company has financial flexibility to fund development. However, risks include trial failures, declining COVID-19 revenue, and regulatory delays. | View source ↗ | The Motley Fool | Oct 17, 2026 | bullish | 0.2 | 1 |
| The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going | The article examines the six best-performing Nasdaq-100 stocks in 2026, led by Moderna (up 667%), followed by SanDisk, Micron Technology, Marvell Technology, AMD, and Intel. While these stocks have benefited from AI-driven demand and strong fundamentals, the article cautions that their massive gains may already be priced in, making future performance uncertain. Past performance does not guarantee future results, as illustrated by examples like Novo Nordisk, which surged in 2023 but declined in 2024. | View source ↗ | The Motley Fool | Oct 17, 2026 | bullish | 0.778 | 1 |
| Moderna falls ahead of cancer vaccine data next week - Seeking Alpha | Moderna falls ahead of cancer vaccine data next week Seeking Alpha | View source ↗ | Seeking Alpha | Oct 16, 2026 | neutral | 0 | 0.6 |
| Moderna stock sinks as Wall Street turns cautious following blistering rally - Yahoo Finance | Moderna stock sinks as Wall Street turns cautious following blistering rally Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| Why is Moderna stock dropping today? - Investing.com | Why is Moderna stock dropping today? Investing.com | View source ↗ | Investing.com | Oct 16, 2026 | neutral | 0 | 0.6 |
| MRNA Stock Jumps 14% Past $150 As Wolfe Sees $9.2B Cancer-Vaccine Opportunity - Stocktwits | MRNA Stock Jumps 14% Past $150 As Wolfe Sees $9.2B Cancer-Vaccine Opportunity Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? | Moderna stock has surged over 600% in 2026, outperforming major AI stocks like Nvidia, Micron, and Sandisk, driven by progress in its oncology pipeline, particularly its personalized cancer vaccine candidate intismeran autogene. The stock now trades 61% above Wall Street's average price target of $122, and while the company shows promise as it transforms from a coronavirus vaccine company into a broader biotech player, the analyst recommends waiting for a pullback before buying. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.4 | 1 |
| Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? | Moderna stock has surged over 600% in 2026, outperforming major AI stocks like Nvidia, Micron, and Sandisk, driven by progress in its oncology pipeline, particularly its personalized cancer vaccine candidate intismeran autogene. The stock now trades 61% above Wall Street's average price target of $122, and while the company shows promise as it transforms from a coronavirus vaccine company into a broader biotech player, the analyst recommends waiting for a pullback before buying. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.4 | 1 |
| Why Did MRNA, KO, V Stocks Climb To 52-Week Highs Today? - Yahoo Finance | Why Did MRNA, KO, V Stocks Climb To 52-Week Highs Today? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| Moderna Stock Jumps 4.5% as Major Cancer Vaccine Catalyst Approaches - TipRanks | Moderna Stock Jumps 4.5% as Major Cancer Vaccine Catalyst Approaches TipRanks | View source ↗ | TipRanks | Oct 15, 2026 | neutral | 0 | 0.6 |
| MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data - Yahoo Finance | MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In? - Yahoo Finance | Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In? - 24/7 Wall St. | Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In? 24/7 Wall St. | View source ↗ | 24/7 Wall St. | Oct 15, 2026 | neutral | 0 | 0.6 |
| MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? | Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? | Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential. | View source ↗ | The Motley Fool | Oct 13, 2026 | neutral | 0.143 | 1 |
| Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential. | View source ↗ | The Motley Fool | Oct 13, 2026 | neutral | 0.143 | 1 |
| Moderna Stock Puts MRNA Cancer Vaccine Shares Back In Focus - Simply Wall Street | Moderna Stock Puts MRNA Cancer Vaccine Shares Back In Focus Simply Wall Street | View source ↗ | Simply Wall Street | Oct 12, 2026 | neutral | 0 | 0.6 |
| Where Could Moderna’s Next Growth Come From? - Trefis | Where Could Moderna’s Next Growth Come From? Trefis | View source ↗ | Trefis | Oct 12, 2026 | neutral | 0 | 0.6 |
| Here's Why Moderna (MRNA) Fell More Than Broader Market | Moderna (MRNA) declined 5.05% to $213.63 in the latest trading session, underperforming the S&P 500. Despite a 56.28% gain over the past month, the company faces headwinds with projected quarterly EPS of -$1.37 (down 168.63% YoY) and revenue expected at $888.78 million (down 12.52% YoY). The stock holds a Zacks Rank #3 (Hold) rating with consensus EPS estimates revised 0.35% lower in the past month. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bearish | -1 | 1 |
| Moderna stock surges more than 600% in 2026 - Quartz | Moderna stock surges more than 600% in 2026 Quartz | View source ↗ | Quartz | Oct 12, 2026 | neutral | 0 | 0.6 |
| Tempus AI Expands Strategic Collaborations to Drive Future Growth | Tempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.833 | 1 |
| Moderna’s (MRNA) Cancer Vaccine Breakthrough Drives Sharp Stock Rally - Yahoo Finance | Moderna’s (MRNA) Cancer Vaccine Breakthrough Drives Sharp Stock Rally Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| Why Did MRNA, HUM, LITE Stocks Surge To 52-Week Highs Last Week? - Yahoo Finance | Why Did MRNA, HUM, LITE Stocks Surge To 52-Week Highs Last Week? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| Moderna (MRNA) Stock Sees Modest Fair Value Lift After Cancer Vaccine Analyst Revisions - Yahoo Finance | Moderna (MRNA) Stock Sees Modest Fair Value Lift After Cancer Vaccine Analyst Revisions Yahoo Finance | View source ↗ | Yahoo Finance | Oct 11, 2026 | neutral | 0 | 0.6 |
| Why Moderna Stock Surged Today - Yahoo Finance | Why Moderna Stock Surged Today Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Moderna gains 14% to set fresh 52-week high (MRNA:NASDAQ) - Seeking Alpha | Moderna gains 14% to set fresh 52-week high (MRNA:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 9, 2026 | neutral | 0 | 0.6 |
| Moderna Stock (MRNA) Climbs 13% to Top Its 52-Week High — Here’s Why - TipRanks | Moderna Stock (MRNA) Climbs 13% to Top Its 52-Week High — Here’s Why TipRanks | View source ↗ | TipRanks | Oct 9, 2026 | neutral | 0 | 0.6 |
| Moderna Stock Hits New 52-Week High: What's Happening? - Benzinga | Moderna Stock Hits New 52-Week High: What's Happening? Benzinga | View source ↗ | Benzinga | Oct 9, 2026 | neutral | 0 | 0.6 |
| Moderna stock fires past 52-week high: what's behind Friday's rally? - TradingView | Moderna stock fires past 52-week high: what's behind Friday's rally? TradingView | View source ↗ | TradingView | Oct 9, 2026 | neutral | 0 | 0.6 |
| Why is Moderna stock surging today? - Investing.com | Why is Moderna stock surging today? Investing.com | View source ↗ | Investing.com | Oct 9, 2026 | neutral | 0 | 0.6 |
| Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock? | Moderna (MRNA) will be added to the Nasdaq-100 Index on October 9, replacing Warner Bros. Discovery following its acquisition by Paramount. The inclusion comes after Moderna's 566% year-to-date stock surge and positive phase III results for its personalized cancer therapy developed with Merck. While the index addition could drive incremental institutional demand through index-tracking funds managing over $800 billion in assets, it does not change the company's underlying fundamentals. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.5 | 1 |
| Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock? | Moderna (MRNA) will be added to the Nasdaq-100 Index on October 9, replacing Warner Bros. Discovery following its acquisition by Paramount. The inclusion comes after Moderna's 566% year-to-date stock surge and positive phase III results for its personalized cancer therapy developed with Merck. While the index addition could drive incremental institutional demand through index-tracking funds managing over $800 billion in assets, it does not change the company's underlying fundamentals. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.5 | 1 |
| Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now? | The article provides an in-depth analysis of the Invesco S&P 500 Equal Weight ETF (RSP), a smart beta ETF with $95.93 billion in assets. RSP uses equal-weighting methodology rather than traditional market cap weighting, with a 0.20% expense ratio and 1.51% dividend yield. The fund has gained 11.2% year-to-date and 12.31% over the past year, with a beta of 0.92. The article compares RSP to alternative cap-weighted ETFs like IVV and VOO, which offer lower expense ratios (0.03%) and potentially lower risk for investors seeking traditional market exposure. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.5 | 1 |
| Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now? | The article provides an in-depth analysis of the Invesco S&P 500 Equal Weight ETF (RSP), a smart beta ETF with $95.93 billion in assets. RSP uses equal-weighting methodology rather than traditional market cap weighting, with a 0.20% expense ratio and 1.51% dividend yield. The fund has gained 11.2% year-to-date and 12.31% over the past year, with a beta of 0.92. The article compares RSP to alternative cap-weighted ETFs like IVV and VOO, which offer lower expense ratios (0.03%) and potentially lower risk for investors seeking traditional market exposure. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.5 | 1 |
| Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? | Merck's stock declined 7.2% recently after a strong 60% annual gain, but analysts view this as a healthy pullback. While the company faces near-term headwinds including Gardasil weakness, generic competition, and Keytruda's 2028 patent expiration, its expanding pipeline with 20 new drug launches expected by 2030 and strategic acquisitions position it for long-term growth. The company maintains a Hold rating with potential as a buying opportunity for long-term investors. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? | Merck's stock declined 7.2% recently after a strong 60% annual gain, but analysts view this as a healthy pullback. While the company faces near-term headwinds including Gardasil weakness, generic competition, and Keytruda's 2028 patent expiration, its expanding pipeline with 20 new drug launches expected by 2030 and strategic acquisitions position it for long-term growth. The company maintains a Hold rating with potential as a buying opportunity for long-term investors. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory. | View source ↗ | The Motley Fool | Oct 2, 2026 | neutral | 0 | 1 |
| Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory. | View source ↗ | The Motley Fool | Oct 2, 2026 | neutral | 0 | 1 |
| Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026 | Nasdaq announced that Moderna, Inc. (MRNA) will replace Warner Bros. Discovery, Inc. (WBD) as a component of the Nasdaq-100 Index effective October 9, 2026. The Nasdaq-100 Index tracks 100 of the largest Nasdaq-listed non-financial companies and is tracked by over 200 investment products with $800 billion in assets under management globally. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | neutral | 0 | 1 |
| Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026 | Nasdaq announced that Moderna, Inc. (MRNA) will replace Warner Bros. Discovery, Inc. (WBD) as a component of the Nasdaq-100 Index effective October 9, 2026. The Nasdaq-100 Index tracks 100 of the largest Nasdaq-listed non-financial companies and is tracked by over 200 investment products with $800 billion in assets under management globally. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | neutral | 0 | 1 |
| Moderna (MRNA) Stock Dips While Market Gains: Key Facts | Moderna (MRNA) closed at $188.94, down 1.89% in the latest session, underperforming the S&P 500. Despite a strong monthly gain of 27.69%, the company faces headwinds with projected earnings of -$1.36 per share (down 166.67% YoY) and quarterly revenue expected at $888.78 million (down 12.52%). The stock holds a Zacks Rank #3 (Hold) rating with unchanged consensus estimates over the past 30 days. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bearish | -1 | 1 |
| Moderna (MRNA) Stock Dips While Market Gains: Key Facts | Moderna (MRNA) closed at $188.94, down 1.89% in the latest session, underperforming the S&P 500. Despite a strong monthly gain of 27.69%, the company faces headwinds with projected earnings of -$1.36 per share (down 166.67% YoY) and quarterly revenue expected at $888.78 million (down 12.52%). The stock holds a Zacks Rank #3 (Hold) rating with unchanged consensus estimates over the past 30 days. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bearish | -1 | 1 |
| Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III - 24/7 Wall St. | Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III 24/7 Wall St. | View source ↗ | 24/7 Wall St. | Sep 1, 2026 | neutral | 0 | 0.6 |
| Is It Too Late to Buy Moderna Stock After Its 127% Surge? - The Motley Fool | Is It Too Late to Buy Moderna Stock After Its 127% Surge? The Motley Fool | View source ↗ | The Motley Fool | Aug 30, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.